The Portnoy Law Firm has announced a class action lawsuit on behalf of investors of Regencell Bioscience Holdings Limited who purchased shares between October 28, 2024, and October 31, 2025. The lawsuit alleges that Regencell made false or misleading statements and failed to disclose vulnerabilities to market manipulation and the resulting financial risks. On October 31, 2025, Regencell revealed a DOJ investigation into trading activities, which led to a significant drop in its share price. Investors have until June 23, 2026, to file a lead plaintiff motion to join the case and seek recovery for losses.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
